Delaware
|
|
22-1760285
|
(State or other jurisdiction of
|
|
(I.R.S. employer
|
incorporation or organization)
|
|
identification no.)
|
150 Clove Road, Little Falls, New Jersey
|
|
07424
|
|
(973) 890-7220
|
(Address of principal executive offices)
|
|
(Zip code)
|
|
(Registrant's telephone number, including area code)
|
Large accelerated filer
☒
|
Accelerated filer ☐
|
Non-accelerated filer ☐
|
Smaller reporting company ☐
|
Emerging growth company ☐
|
|
|
Page No.
|
|
PART I – FINANCIAL INFORMATION
|
|
Item 1.
|
Financial Statements
(unaudited)
|
|
|
Condensed Consolidated Balance Sheets
(unaudited)
|
|
|
Condensed Consolidated Statements of Income
(unaudited)
|
|
|
||
|
Condensed Consolidated Statements of Cash Flows
(unaudited)
|
|
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
PART II – OTHER INFORMATION
|
|
Item 1.
|
||
Item 1A.
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
Item 5.
|
||
Item 6.
|
||
Signatures
|
|
|
October 31, 2018
|
|
July 31, 2018
|
||||
Assets
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
64,030
|
|
|
$
|
94,097
|
|
Accounts receivable, net of allowance for doubtful accounts of $1,378 and $1,149
|
125,140
|
|
|
118,642
|
|
||
Inventories, net
|
111,071
|
|
|
107,592
|
|
||
Prepaid expenses and other current assets
|
17,340
|
|
|
17,912
|
|
||
Total current assets
|
317,581
|
|
|
338,243
|
|
||
|
|
|
|
||||
Property and equipment, net
|
148,584
|
|
|
111,417
|
|
||
Intangible assets, net
|
137,758
|
|
|
137,361
|
|
||
Goodwill
|
370,878
|
|
|
368,027
|
|
||
Other assets
|
5,512
|
|
|
5,749
|
|
||
Deferred income taxes
|
3,286
|
|
|
2,911
|
|
||
Total assets
|
$
|
983,599
|
|
|
$
|
963,708
|
|
|
|
|
|
||||
Liabilities and stockholders’ equity
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
41,984
|
|
|
$
|
34,258
|
|
Compensation payable
|
23,875
|
|
|
30,595
|
|
||
Accrued expenses
|
31,274
|
|
|
28,525
|
|
||
Deferred revenue
|
29,280
|
|
|
28,614
|
|
||
Current portion of long-term debt
|
10,000
|
|
|
10,000
|
|
||
Income taxes payable
|
7,374
|
|
|
2,791
|
|
||
Total current liabilities
|
143,787
|
|
|
134,783
|
|
||
|
|
|
|
||||
Long-term debt
|
184,940
|
|
|
187,302
|
|
||
Deferred income taxes
|
27,326
|
|
|
27,624
|
|
||
Other long-term liabilities
|
5,186
|
|
|
5,132
|
|
||
Total liabilities
|
361,239
|
|
|
354,841
|
|
||
Commitments and contingencies (Note 11)
|
|
|
|
|
|
||
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
|
|
||
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued
|
$
|
—
|
|
|
$
|
—
|
|
Common Stock, par value $0.10 per share; authorized 75,000,000 shares; issued 46,307,058 shares and outstanding 41,721,316 shares as of October 31, 2018; issued 46,243,582 shares and outstanding 41,706,084 shares as of July 31, 2018
|
4,631
|
|
|
4,624
|
|
||
Additional paid-in capital
|
187,102
|
|
|
184,212
|
|
||
Retained earnings
|
511,647
|
|
|
491,540
|
|
||
Accumulated other comprehensive loss
|
(16,679
|
)
|
|
(11,456
|
)
|
||
Treasury Stock, at cost; 4,585,742 shares as of October 31, 2018; 4,537,498 shares as of
July 31, 2018 |
(64,341
|
)
|
|
(60,053
|
)
|
||
Total stockholders’ equity
|
622,360
|
|
|
608,867
|
|
||
Total liabilities and stockholders' equity
|
$
|
983,599
|
|
|
$
|
963,708
|
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Net sales
|
|
|
|
|
|
||
Product sales
|
$
|
195,760
|
|
|
$
|
187,965
|
|
Product service
|
29,829
|
|
|
24,801
|
|
||
Total net sales
|
225,589
|
|
|
212,766
|
|
||
|
|
|
|
||||
Cost of sales
|
|
|
|
|
|
||
Product sales
|
99,310
|
|
|
95,099
|
|
||
Product service
|
21,030
|
|
|
17,008
|
|
||
Total cost of sales
|
120,340
|
|
|
112,107
|
|
||
|
|
|
|
||||
Gross profit
|
105,249
|
|
|
100,659
|
|
||
|
|
|
|
||||
Expenses:
|
|
|
|
||||
Selling
|
33,958
|
|
|
31,600
|
|
||
General and administrative
|
36,535
|
|
|
32,096
|
|
||
Research and development
|
7,078
|
|
|
5,329
|
|
||
Total operating expenses
|
77,571
|
|
|
69,025
|
|
||
|
|
|
|
||||
Income from operations
|
27,678
|
|
|
31,634
|
|
||
|
|
|
|
||||
Interest expense, net
|
2,026
|
|
|
1,189
|
|
||
Other income
|
—
|
|
|
(1,138
|
)
|
||
|
|
|
|
||||
Income before income taxes
|
25,652
|
|
|
31,583
|
|
||
|
|
|
|
||||
Income taxes
|
6,410
|
|
|
8,654
|
|
||
|
|
|
|
||||
Net income
|
$
|
19,242
|
|
|
$
|
22,929
|
|
|
|
|
|
||||
Earnings per common share:
|
|
|
|
|
|
||
Basic
|
$
|
0.46
|
|
|
$
|
0.55
|
|
Diluted
|
$
|
0.46
|
|
|
$
|
0.55
|
|
Dividends per common share
|
$
|
—
|
|
|
$
|
—
|
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Net income
|
$
|
19,242
|
|
|
$
|
22,929
|
|
|
|
|
|
||||
Other comprehensive loss:
|
|
|
|
|
|
||
Foreign currency translation
|
(5,223
|
)
|
|
(1,233
|
)
|
||
Total other comprehensive loss
|
(5,223
|
)
|
|
(1,233
|
)
|
||
|
|
|
|
||||
Comprehensive income
|
$
|
14,019
|
|
|
$
|
21,696
|
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Cash flows from operating activities
|
|
|
|
|
|
||
Net income
|
$
|
19,242
|
|
|
$
|
22,929
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation
|
4,691
|
|
|
4,036
|
|
||
Amortization
|
6,041
|
|
|
4,048
|
|
||
Stock-based compensation expense
|
2,576
|
|
|
1,851
|
|
||
Deferred income taxes
|
(674
|
)
|
|
780
|
|
||
Other non-cash items, net
|
1,236
|
|
|
(67
|
)
|
||
Changes in assets and liabilities, net of effects of business acquisitions:
|
|
|
|
|
|
||
Accounts receivable
|
(4,087
|
)
|
|
8,584
|
|
||
Inventories
|
(3,359
|
)
|
|
(2,629
|
)
|
||
Prepaid expenses and other assets
|
1,089
|
|
|
(6,273
|
)
|
||
Accounts payable and other liabilities
|
1,055
|
|
|
(6,679
|
)
|
||
Income taxes
|
4,459
|
|
|
3,492
|
|
||
Net cash provided by operating activities
|
32,269
|
|
|
30,072
|
|
||
|
|
|
|
||||
Cash flows from investing activities
|
|
|
|
|
|
||
Capital expenditures
|
(38,834
|
)
|
|
(6,492
|
)
|
||
Acquisition of businesses, net of cash acquired
|
(17,000
|
)
|
|
(60,345
|
)
|
||
Net cash used in investing activities
|
(55,834
|
)
|
|
(66,837
|
)
|
||
|
|
|
|
||||
Cash flows from financing activities
|
|
|
|
|
|
||
Repayments of long-term debt
|
(2,500
|
)
|
|
—
|
|
||
Borrowings under revolving credit facility
|
—
|
|
|
61,300
|
|
||
Repayments under revolving credit facility
|
—
|
|
|
(19,300
|
)
|
||
Purchases of treasury stock
|
(4,288
|
)
|
|
(5,822
|
)
|
||
Net cash (used in) provided by financing activities
|
(6,788
|
)
|
|
36,178
|
|
||
|
|
|
|
||||
Effect of exchange rate changes on cash and cash equivalents
|
286
|
|
|
1,223
|
|
||
|
|
|
|
||||
(Decrease) increase in cash and cash equivalents
|
(30,067
|
)
|
|
636
|
|
||
Cash and cash equivalents at beginning of period
|
94,097
|
|
|
36,584
|
|
||
Cash and cash equivalents at end of period
|
$
|
64,030
|
|
|
$
|
37,220
|
|
3.
|
Acquisitions
|
|
|
2019
|
|
2018
|
||||||||
Purchase Price Allocation
|
|
CES Business
(1)
|
|
Aexis
(1)
|
|
BHT Group
(1)
|
||||||
|
|
(Preliminary)
|
|
(Preliminary)
|
|
(Final)
|
||||||
Purchase Price:
|
|
|
|
|
|
|
||||||
Cash paid
|
|
$
|
17,000
|
|
|
$
|
20,308
|
|
|
$
|
60,216
|
|
Fair value of contingent consideration
|
|
—
|
|
|
1,292
|
|
|
—
|
|
|||
Total
|
|
$
|
17,000
|
|
|
$
|
21,600
|
|
|
$
|
60,216
|
|
|
|
|
|
|
|
|
||||||
Allocation:
|
|
|
|
|
|
|
||||||
Property and equipment
|
|
548
|
|
|
130
|
|
|
835
|
|
|||
Amortizable intangible assets:
|
|
|
|
|
|
|
||||||
Customer relationships
|
|
8,100
|
|
|
1,800
|
|
|
12,500
|
|
|||
Technology
|
|
—
|
|
|
4,600
|
|
|
6,200
|
|
|||
Goodwill
|
|
6,129
|
|
|
17,092
|
|
|
40,934
|
|
|||
Deferred income taxes
|
|
—
|
|
|
(1,639
|
)
|
|
(5,881
|
)
|
|||
Other working capital
|
|
2,223
|
|
|
909
|
|
|
5,628
|
|
|||
Contingent consideration
|
|
—
|
|
|
(1,292
|
)
|
|
—
|
|
|||
Total
|
|
$
|
17,000
|
|
|
$
|
21,600
|
|
|
$
|
60,216
|
|
(1)
|
The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Cost of sales
|
$
|
237
|
|
|
$
|
115
|
|
Operating expenses:
|
|
|
|
|
|
||
Selling
|
571
|
|
|
365
|
|
||
General and administrative
|
1,710
|
|
|
1,333
|
|
||
Research and development
|
58
|
|
|
38
|
|
||
Total operating expenses
|
2,339
|
|
|
1,736
|
|
||
Stock-based compensation expense
|
$
|
2,576
|
|
|
$
|
1,851
|
|
|
Three Months Ended October 31,
|
||||
|
2018
|
|
2017
|
||
Volatility of common stock
|
27.54
|
%
|
|
26.60
|
%
|
Average volatility of peer companies
|
36.55
|
%
|
|
33.72
|
%
|
Average correlation coefficient of peer companies
|
27.18
|
%
|
|
32.26
|
%
|
Risk-free interest rate
|
2.93
|
%
|
|
1.62
|
%
|
|
|
Number of
Time-based Awards
|
|
Number of Performance-based Awards
|
|
Number of Market-based Awards
|
|
Number of
Total
Awards
|
|
Weighted Average
Fair Value
|
||||||
July 31, 2018
|
|
168,320
|
|
|
26,076
|
|
|
17,710
|
|
|
212,106
|
|
|
$
|
88.87
|
|
Granted
|
|
117,832
|
|
|
27,336
|
|
|
16,765
|
|
|
161,933
|
|
|
$
|
91.91
|
|
Vested
(1)
|
|
(80,728
|
)
|
|
(10,235
|
)
|
|
—
|
|
|
(90,963
|
)
|
|
$
|
76.16
|
|
Forfeited
|
|
(1,254
|
)
|
|
—
|
|
|
—
|
|
|
(1,254
|
)
|
|
$
|
88.01
|
|
October 31, 2018
|
|
204,170
|
|
|
43,177
|
|
|
34,475
|
|
|
281,822
|
|
|
$
|
94.95
|
|
(1)
|
The aggregate fair value of all nonvested stock awards which vested was approximately
$6,930
.
|
|
Number of shares
|
|
Weighted Average Exercise Price
|
|
Weighted Average Contractual Life Remaining (Years)
|
|
Aggregate Intrinsic Value
|
|||||
Outstanding at July 31, 2018
|
70,000
|
|
|
$
|
38.60
|
|
|
|
|
|
||
Exercised
|
(30,000
|
)
|
|
31.81
|
|
|
|
|
|
|||
Outstanding at October 31, 2018
|
40,000
|
|
|
$
|
43.70
|
|
|
1.32
|
|
$
|
1,418
|
|
Exercisable at October 31, 2018
|
40,000
|
|
|
$
|
43.70
|
|
|
1.32
|
|
$
|
1,418
|
|
|
Three Months Ended October 31,
|
||||||
Net sales by geography
|
2018
|
|
2017
(1)
|
||||
United States
|
$
|
168,938
|
|
|
$
|
160,940
|
|
Europe/Africa/Middle East
|
32,014
|
|
|
28,101
|
|
||
Asia/Pacific
|
15,752
|
|
|
13,607
|
|
||
Canada
|
7,373
|
|
|
8,476
|
|
||
Latin America/South America
|
1,512
|
|
|
1,642
|
|
||
Total
|
$
|
225,589
|
|
|
$
|
212,766
|
|
Net sales by product line
|
|
|
|
||||
Capital equipment
|
$
|
58,132
|
|
|
$
|
59,169
|
|
Consumables
|
136,821
|
|
|
128,359
|
|
||
Product service
|
29,829
|
|
|
24,801
|
|
||
All other
(2)
|
807
|
|
|
437
|
|
||
Total
|
$
|
225,589
|
|
|
$
|
212,766
|
|
(1)
|
As noted above, prior year amounts have not been adjusted under the modified retrospective method.
|
(2)
|
Primarily includes software licensing revenues.
|
|
Contract Liabilities
|
||
Balance, August 1, 2018
|
$
|
29,015
|
|
Revenue deferred in current year
|
14,524
|
|
|
Deferred revenue recognized
|
(13,547
|
)
|
|
Foreign currency translation
|
(163
|
)
|
|
Balance, October 31, 2018
|
29,829
|
|
|
Contract liabilities included in Other long-term liabilities
|
(549
|
)
|
|
Deferred revenue
|
$
|
29,280
|
|
|
October 31, 2018
|
|
July 31, 2018
|
||||
Raw materials and parts
|
$
|
53,097
|
|
|
$
|
49,054
|
|
Work-in-process
|
14,122
|
|
|
13,189
|
|
||
Finished goods
|
52,348
|
|
|
53,948
|
|
||
Reserve for excess and obsolete inventory
|
(8,496
|
)
|
|
(8,599
|
)
|
||
Total
|
$
|
111,071
|
|
|
$
|
107,592
|
|
|
October 31, 2018
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money markets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Total assets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other long-term liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Contingent consideration
|
—
|
|
|
—
|
|
|
1,320
|
|
|
1,320
|
|
||||
Total liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,320
|
|
|
$
|
1,320
|
|
|
July 31, 2018
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money markets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Total assets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other long-term liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Contingent obligation
|
—
|
|
|
—
|
|
|
1,298
|
|
|
1,298
|
|
||||
Total liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,298
|
|
|
$
|
1,298
|
|
|
Aexis Contingent Consideration
|
|
Jet Prep Assumed Contingent Obligation
|
|
Total
|
||||||
Balance, July 31, 2018
|
$
|
1,298
|
|
|
$
|
—
|
|
|
$
|
1,298
|
|
Loss included in general and administrative expense
|
22
|
|
|
—
|
|
|
22
|
|
|||
Net purchases, issuances, sales and settlements
|
—
|
|
|
—
|
|
|
—
|
|
|||
Balance, October 31, 2018
|
$
|
1,320
|
|
|
$
|
—
|
|
|
$
|
1,320
|
|
9.
|
Intangibles and Goodwill
|
|
October 31, 2018
|
|
July 31, 2018
|
||||||||||||||||||||
|
Gross
|
|
Accumulated Amortization
|
|
Net
|
|
Gross
|
|
Accumulated Amortization
|
|
Net
|
||||||||||||
Intangible assets with finite lives:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Customer relationships
(1)
|
$
|
134,866
|
|
|
$
|
(43,177
|
)
|
|
$
|
91,689
|
|
|
$
|
133,347
|
|
|
$
|
(45,618
|
)
|
|
$
|
87,729
|
|
Technology
(1)
|
50,918
|
|
|
(18,724
|
)
|
|
32,194
|
|
|
54,585
|
|
|
(19,836
|
)
|
|
34,749
|
|
||||||
Brand names
(1)
|
6,874
|
|
|
(2,774
|
)
|
|
4,100
|
|
|
8,141
|
|
|
(3,857
|
)
|
|
4,284
|
|
||||||
Non-compete agreements
(1)
|
2,880
|
|
|
(1,505
|
)
|
|
1,375
|
|
|
3,060
|
|
|
(1,628
|
)
|
|
1,432
|
|
||||||
Patents and other registrations
|
2,855
|
|
|
(1,150
|
)
|
|
1,705
|
|
|
2,826
|
|
|
(1,179
|
)
|
|
1,647
|
|
||||||
|
198,393
|
|
|
(67,330
|
)
|
|
131,063
|
|
|
201,959
|
|
|
(72,118
|
)
|
|
129,841
|
|
||||||
Trademarks and tradenames
|
6,695
|
|
|
—
|
|
|
6,695
|
|
|
7,520
|
|
|
—
|
|
|
7,520
|
|
||||||
Total intangible assets
|
$
|
205,088
|
|
|
$
|
(67,330
|
)
|
|
$
|
137,758
|
|
|
$
|
209,479
|
|
|
$
|
(72,118
|
)
|
|
$
|
137,361
|
|
(1)
|
During the first quarter of fiscal 2019, we wrote off
$10,335
of fully amortized intangible assets.
|
|
Medical
|
|
Life Sciences
|
|
Dental
|
|
Dialysis
|
|
Total
Goodwill
|
||||||||||
Balance, July 31, 2018
|
$
|
186,690
|
|
|
$
|
58,925
|
|
|
$
|
114,279
|
|
|
$
|
8,133
|
|
|
$
|
368,027
|
|
Acquisitions
|
—
|
|
|
6,129
|
|
|
—
|
|
|
—
|
|
|
6,129
|
|
|||||
Foreign currency translation
|
(3,180
|
)
|
|
(98
|
)
|
|
—
|
|
|
—
|
|
|
(3,278
|
)
|
|||||
Balance, October 31, 2018
|
$
|
183,510
|
|
|
$
|
64,956
|
|
|
$
|
114,279
|
|
|
$
|
8,133
|
|
|
$
|
370,878
|
|
|
October 31, 2018
|
|
July 31, 2018
|
||||
Tranche A term loan outstanding
|
$
|
197,500
|
|
|
$
|
200,000
|
|
Unamortized debt issuance costs
|
(2,560
|
)
|
|
(2,698
|
)
|
||
Total long-term debt, net of unamortized debt issuance costs
|
194,940
|
|
|
197,302
|
|
||
Current portion of long-term debt
|
(10,000
|
)
|
|
(10,000
|
)
|
||
Long-term debt, net of unamortized debt issuance costs and excluding current portion
|
$
|
184,940
|
|
|
$
|
187,302
|
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Numerator for basic and diluted earnings per share:
|
|
|
|
|
|||
Net income
|
$
|
19,242
|
|
|
$
|
22,929
|
|
Less income allocated to participating securities
|
(33
|
)
|
|
(124
|
)
|
||
Net income available to common shareholders
|
$
|
19,209
|
|
|
$
|
22,805
|
|
Denominator for basic and diluted earnings per share, adjusted for participating securities:
|
|
|
|
|
|||
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock
|
41,640,745
|
|
|
41,521,952
|
|
||
Dilutive effect of stock awards using the treasury stock method and the average market price for the year
|
65,028
|
|
|
66,233
|
|
||
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock
|
41,705,773
|
|
|
41,588,185
|
|
||
Earnings per share attributable to common stock:
|
|
|
|
|
|||
Basic earnings per share
|
$
|
0.46
|
|
|
$
|
0.55
|
|
Diluted earnings per share
|
$
|
0.46
|
|
|
$
|
0.55
|
|
Stock options excluded from weighted average dilutive common shares because their inclusion would have been anti-dilutive
|
—
|
|
|
—
|
|
|
Three Months Ended October 31,
|
||||
|
2018
|
|
2017
|
||
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock
|
41,705,773
|
|
|
41,588,185
|
|
Participating securities
|
69,452
|
|
|
225,675
|
|
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities
|
41,775,225
|
|
|
41,813,860
|
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Beginning balance
|
$
|
(11,456
|
)
|
|
$
|
(9,900
|
)
|
Other comprehensive loss for foreign currency translation
|
(5,223
|
)
|
|
(1,233
|
)
|
||
Ending balance
|
$
|
(16,679
|
)
|
|
$
|
(11,133
|
)
|
|
Three Months Ended October 31,
|
||||||
Income from operations
|
2018
|
|
2017
|
||||
Medical
|
$
|
25,211
|
|
|
$
|
19,684
|
|
Life Sciences
|
6,331
|
|
|
10,375
|
|
||
Dental
|
5,925
|
|
|
8,675
|
|
||
Dialysis
|
1,384
|
|
|
2,099
|
|
||
|
38,851
|
|
|
40,833
|
|
||
General corporate expenses
|
11,173
|
|
|
9,199
|
|
||
Total income from operations
|
$
|
27,678
|
|
|
$
|
31,634
|
|
•
|
Net sales increased by
6.0%
to
$225,589
from
$212,766
, with organic net sales growth of
4.3%
|
•
|
Net income decreased by
16.1%
to
$19,242
from
$22,929
|
•
|
Non-GAAP net income increased by
7.7%
to
$25,891
from
$24,041
|
•
|
Diluted EPS decreased by
16.0%
to
$0.46
from
$0.55
|
•
|
Non-GAAP diluted EPS increased by
7.9%
to
$0.62
from
$0.57
|
•
|
Adjusted EBITDAS increased by
0.8%
to
$44,771
from
$44,395
|
|
Three Months Ended October 31,
|
|
Percentage Change
|
|||||||||||
Statement of Income Data:
|
2018
|
|
2017
|
|
||||||||||
Net sales
|
$
|
225,589
|
|
100.0
|
%
|
|
$
|
212,766
|
|
100.0
|
%
|
|
6.0
|
%
|
Cost of sales
|
120,340
|
|
53.3
|
%
|
|
112,107
|
|
52.7
|
%
|
|
7.3
|
%
|
||
Gross profit
|
105,249
|
|
46.7
|
%
|
|
100,659
|
|
47.3
|
%
|
|
4.6
|
%
|
||
|
|
|
|
|
|
|
|
|||||||
Selling
|
33,958
|
|
15.1
|
%
|
|
31,600
|
|
14.8
|
%
|
|
7.5
|
%
|
||
General and administrative
|
36,535
|
|
16.2
|
%
|
|
32,096
|
|
15.1
|
%
|
|
13.8
|
%
|
||
Research and development
|
7,078
|
|
3.1
|
%
|
|
5,329
|
|
2.5
|
%
|
|
32.8
|
%
|
||
Total operating expenses
|
77,571
|
|
34.4
|
%
|
|
69,025
|
|
32.4
|
%
|
|
12.4
|
%
|
||
|
|
|
|
|
|
|
|
|||||||
Income from operations
|
27,678
|
|
12.3
|
%
|
|
31,634
|
|
14.9
|
%
|
|
(12.5
|
)%
|
||
|
|
|
|
|
|
|
|
|||||||
Interest expense, net
|
2,026
|
|
0.9
|
%
|
|
1,189
|
|
0.6
|
%
|
|
70.4
|
%
|
||
Other income
|
—
|
|
—
|
%
|
|
(1,138
|
)
|
(0.5
|
)%
|
|
—
|
%
|
||
Income before income taxes
|
25,652
|
|
11.4
|
%
|
|
31,583
|
|
14.8
|
%
|
|
(18.8
|
)%
|
||
Income taxes
|
6,410
|
|
2.9
|
%
|
|
8,654
|
|
4.0
|
%
|
|
(25.9
|
)%
|
||
Net income
|
$
|
19,242
|
|
8.5
|
%
|
|
$
|
22,929
|
|
10.8
|
%
|
|
(16.1
|
)%
|
|
Three Months Ended October 31,
|
||||||||||
Net sales by segment
|
2018
|
|
2017
|
||||||||
Medical
|
$
|
127,552
|
|
56.5
|
%
|
|
$
|
112,385
|
|
52.8
|
%
|
Life Sciences
|
53,345
|
|
23.6
|
%
|
|
54,770
|
|
25.7
|
%
|
||
Dental
|
36,628
|
|
16.2
|
%
|
|
37,677
|
|
17.7
|
%
|
||
Dialysis
|
8,064
|
|
3.7
|
%
|
|
7,934
|
|
3.8
|
%
|
||
Total net sales
|
$
|
225,589
|
|
100.0
|
%
|
|
$
|
212,766
|
|
100.0
|
%
|
Net sales by geography
|
|
|
|
|
|
|
|
||||
United States
|
$
|
168,938
|
|
74.9
|
%
|
|
$
|
160,940
|
|
75.6
|
%
|
International
|
56,651
|
|
25.1
|
%
|
|
51,826
|
|
24.4
|
%
|
||
Total net sales
|
$
|
225,589
|
|
100.0
|
%
|
|
$
|
212,766
|
|
100.0
|
%
|
|
Three Months Ended October 31,
|
||||||||||
Income from operations by segment
|
2018
|
|
2017
|
||||||||
Medical
|
$
|
25,211
|
|
19.8
|
%
|
|
$
|
19,684
|
|
17.5
|
%
|
Life Sciences
|
6,331
|
|
11.9
|
%
|
|
10,375
|
|
18.9
|
%
|
||
Dental
|
5,925
|
|
16.2
|
%
|
|
8,675
|
|
23.0
|
%
|
||
Dialysis
|
1,384
|
|
17.2
|
%
|
|
2,099
|
|
26.5
|
%
|
||
Income from operations by segment
|
38,851
|
|
17.2
|
%
|
|
40,833
|
|
19.2
|
%
|
||
General corporate expenses
|
11,173
|
|
4.9
|
%
|
|
9,199
|
|
4.3
|
%
|
||
Income from operations
|
$
|
27,678
|
|
12.3
|
%
|
|
$
|
31,634
|
|
14.9
|
%
|
|
Three Months Ended October 31,
|
||||||||||||||
|
2018
|
|
2017
|
||||||||||||
Net income/Diluted EPS, as reported
|
$
|
19,242
|
|
|
$
|
0.46
|
|
|
$
|
22,929
|
|
|
$
|
0.55
|
|
Intangible amortization, net of tax
(1)
|
4,626
|
|
|
0.11
|
|
|
2,869
|
|
|
0.07
|
|
||||
Acquisition-related items, net of tax
(2)
|
1,349
|
|
|
0.03
|
|
|
1,081
|
|
|
0.03
|
|
||||
Restructuring-related charges, net of tax
(3)
|
641
|
|
|
0.02
|
|
|
586
|
|
|
0.01
|
|
||||
Excess tax benefit
(4)
|
(997
|
)
|
|
(0.02
|
)
|
|
(2,286
|
)
|
|
(0.05
|
)
|
||||
Tax matters
(4)
|
896
|
|
|
0.02
|
|
|
—
|
|
|
—
|
|
||||
Litigation matters
(1)
|
134
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Resolution of contingent liability
(5)
|
—
|
|
|
—
|
|
|
(1,138
|
)
|
|
(0.03
|
)
|
||||
Non-GAAP net income/Non-GAAP diluted EPS
|
$
|
25,891
|
|
|
$
|
0.62
|
|
|
$
|
24,041
|
|
|
$
|
0.57
|
|
(1)
|
Amounts were recorded in general and administrative expenses.
|
(2)
|
For the three months ended
October 31, 2018
, pre-tax acquisition-related items of $217 were recorded in net sales, $54 were recorded in cost of sales and $1,555 were recorded in general and administrative expenses. For the three months ended
October 31, 2017
, pre-tax acquisition-related items of $893 were recorded in cost of sales and $916 were recorded in general and administrative expenses.
|
(3)
|
For the three months ended
October 31, 2018
, pre-tax restructuring-related items of $166 were recorded in cost of sales and $680 were recorded in general and administrative expenses. For the three months ended
October 31, 2017
, pre-tax restructuring-related items of $505 were recorded in cost of sales and $443 were recorded in general and administrative expenses.
|
(4)
|
Amounts were recorded in income taxes.
|
(5)
|
Amounts were recorded in other income.
|
|
Three Months Ended October 31,
|
||||||
|
2018
|
|
2017
|
||||
Net income, as reported
|
$
|
19,242
|
|
|
$
|
22,929
|
|
Interest expense, net
|
2,026
|
|
|
1,189
|
|
||
Income taxes
|
6,410
|
|
|
8,654
|
|
||
Depreciation
|
4,691
|
|
|
4,036
|
|
||
Amortization
|
6,041
|
|
|
4,048
|
|
||
Loss on disposal of fixed assets
|
1,053
|
|
|
69
|
|
||
Stock-based compensation expense
|
2,576
|
|
|
1,851
|
|
||
EBITDAS
|
42,039
|
|
|
42,776
|
|
||
Acquisition-related items
|
1,827
|
|
|
1,809
|
|
||
Restructuring-related charges
(1)
|
742
|
|
|
948
|
|
||
Litigation matters
|
163
|
|
|
—
|
|
||
Resolution of contingent liability
|
—
|
|
|
(1,138
|
)
|
||
Adjusted EBITDAS
|
$
|
44,771
|
|
|
$
|
44,395
|
|
(1)
|
Excludes stock-based compensation expense.
|
|
October 31, 2018
|
|
July 31, 2018
|
||||
Long-term debt (excluding debt issuance costs)
|
$
|
197,500
|
|
|
$
|
200,000
|
|
Less cash and cash equivalents
|
(64,030
|
)
|
|
(94,097
|
)
|
||
Net debt
|
$
|
133,470
|
|
|
$
|
105,903
|
|
Period
|
|
Total number of
shares purchased
|
|
Average price
paid per share
|
|
Total number of shares purchased as part of publicly announced plans or programs
|
|
Maximum number of shares that may yet be purchased under the program
|
|||||
August 1 - August 31
|
|
793
|
|
|
$
|
94.40
|
|
|
—
|
|
|
—
|
|
September 1 - September 30
|
|
59
|
|
|
$
|
96.39
|
|
|
—
|
|
|
—
|
|
October 1 - October 31
|
|
47,392
|
|
|
$
|
88.78
|
|
|
—
|
|
|
—
|
|
Total
|
|
48,244
|
|
|
$
|
88.88
|
|
|
—
|
|
|
—
|
|
|
|
Cantel Medical Corp. 2016 Equity Incentive Plan (as amended through October 31, 2018)
|
|
|
|
|
|
|
|
Certification of Principal Executive Officer.
|
|
|
|
|
|
|
|
Certification of Principal Financial Officer.
|
|
|
|
|
|
|
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
|
|
|
|
|
|
|
101
|
|
The following materials from this report, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements.
|
|
CANTEL MEDICAL CORP.
|
|
|
|
|
Date: November 30, 2018
|
|
|
|
|
|
|
By:
|
/s/ Jorgen B. Hansen
|
|
|
Jorgen B. Hansen,
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
By:
|
/s/ Peter G. Clifford
|
|
|
Peter G. Clifford,
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
By:
|
/s/ Brian R. Capone
|
|
|
Brian R. Capone
|
|
|
Senior Vice President and Chief Accounting Officer
|
|
|
(Principal Accounting Officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Cantel Medical Corp.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
|
Date:
|
November 30, 2018
|
|
|
By:
|
/s/ Jorgen B. Hansen
|
Jorgen B. Hansen, President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Cantel Medical Corp.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
|
Date:
|
November 30, 2018
|
|
|
||
By:
|
/s/ Peter G. Clifford
|
|
Peter G. Clifford, Executive Vice President and Chief Financial Officer
|
||
(Principal Financial Officer)
|
1.
|
The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company, as of the date and for the period referred to in this report.
|
Date:
|
November 30, 2018
|
|
|
|
|
|
|
|
|
|
/s/ Jorgen B. Hansen
|
|
|
Jorgen B. Hansen
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
/s/ Peter G. Clifford
|
|
|
Peter G. Clifford
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
(Principal Financial Officer)
|